

General information about company

Name of The Company	Eiko Lifesciences Ltd
BSE Scrip Code	540204
NSE Symbol	
MSE Symbol	
Date of Start of Financial Year	01-04-2022
Date of End of Financial Year	31-3-2023
Reporting Period	First half yearly
Date of Start of Reporting Period	01-04-2022
Date of End of Reporting Period	30-09-2022
Level of rounding to be used in disclosing related party transactions	Lakhs
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	

Related party transactions

												Additional disclosure of related party transactions relates to loans, inter-corporate deposits, advances or investments. These details need to be disclosed in the financial statements.					
Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Na adv int dep inv
1	Eiko Lifesciences Limited	AAACN0917C	Avi Vijaykumar Mundecha	BUFPM9480C	Company Secretary of the Company	Remuneration		7	None	2.4	0	0					
2	Eiko Lifesciences Limited	AAACN0917C	Umesh Ravindranath More	AFMPM3924L	Whole-Time Director of the Company	Remuneration		7	None	3	0	0					
3	Eiko Lifesciences Limited	AAACN0917C	Jaid Kojar	AYBPK3762E	Chief Financial Officer	Remuneration		9	None	3.6	0	0					
4	Eiko Lifesciences Limited	AAACN0917C	Urvi Speciality Chemical	AABFU0392C	Partnership Firm of Director	Purchase of goods or services		50	None	10.5	0	0					
Total value of transaction during the reporting period										19.5							

